SCHEMBL3055643

SCHEMBL3055643

CS(=O)(=O)c1cccc(NC(=S)NC(=O)c2cccc(Cl)c2)c1

nearest known ligand 0.79

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.72
ALDH1A1 P00352 3/20 0.72
NPC1 O15118 2/20 0.72
RAB9A P51151 2/20 0.72
HPGD P15428 1/20 0.72
CA1 P00915 2/20 0.63
CA2 P00918 2/20 0.63
CA9 Q16790 2/20 0.63
MAPT P10636 1/20 0.60
KMT2A Q03164 2/20 0.58
LMNA P02545 1/20 0.58
MEN1 O00255 1/20 0.58
ADORA3 P0DMS8 1/20 0.57
ADORA2A P29274 1/20 0.57
ADORA2B P29275 1/20 0.57
ADORA1 P30542 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3055603 0.89 SMN1; SMN2 (0.67) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL4439620 0.88 CA1 (0.77) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL3055536 0.87 ALDH1A1 (0.67) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL3046207 0.86 SMN1; SMN2 (0.84) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL3049631 0.83 SMN1; SMN2 (0.79) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL3049551 0.82 NPC1 (0.78) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL3054545 0.80 ALDH1A1 (0.74) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL3051204 0.80 NPC1 (0.74) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL3054219 0.80 SMN1; SMN2 (0.73) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL18606680 0.80 ALDH1A1 (0.74) SMN1; SMN2ALDH1A1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200977-B1 F1F0-ATPASE INHIBITORS AND RELATED METHODS UNIV MICHIGAN (US) 2016-11-09 EP disclosed
US-8324258-B2 F1F0-ATPase inhibitors and related methods THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-12-04 US disclosed
CN-101855203-A F1F0Inhibitors of ATP synthase and related methods UNIV MICHIGAN 2010-10-06 CN disclosed
US-20100222400-A1 F1F0-ATPase Inhibitors and Related Methods THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222400-A1 F1F0-ATPase Inhibitors and Related Methods ATP5F1A, ATP5F1B, ATP5F1D SMN1; SMN2 2992/4885ALDH1A1 2038/4885NPC1 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.